

**RISHI GUPTA, MD**

Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

DERK W. KRIEGER, MD, PhD*

Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Preventing ischemic stroke: Choosing the best strategy

ABSTRACT

Many questions remain about specific strategies to prevent first or subsequent stroke: Do statins prevent stroke? Which antithrombotic drugs are best? What is the best way to treat carotid stenosis? We review current evidence on drug therapy and surgical options, addressing key stroke risk factors: ie, hypertension, atherosclerosis, atrial fibrillation, patent foramen ovale, aortic stenosis, and carotid stenosis.

KEY POINTS

Aggressive lowering of blood pressure and low-density lipoprotein cholesterol levels reduces the risk of stroke.

If the patient has a stroke while taking aspirin, switch to clopidogrel or extended-release dipyridamole plus aspirin and consider platelet aggregation studies to determine if the patient is "aspirin-resistant."

Patients with cardioembolic stroke should undergo extended Holter monitoring for paroxysmal atrial fibrillation, since they may benefit from warfarin as secondary prevention.

Patients with stroke related to a patent foramen ovale can be treated initially with aspirin if they were not already taking aspirin before the event. If the event occurs while a patient is on aspirin therapy, consider percutaneous closure or warfarin, preferably in the setting of a clinical trial.

*Dr. Krieger has indicated that he is on the speakers' bureau of BMS and is a consultant for Boehringer Ingelheim.
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

WE CAN OFTEN PREVENT stroke—be it a first ischemic stroke (ie, primary prevention) or a subsequent stroke (secondary prevention). Current preventive strategies, if properly implemented, can reduce stroke incidence by as much as 50% to 80%.¹

Nevertheless, many questions remain and require further study. For example, is one drug better than another for preventing a second stroke? In which patients is surgical therapy to prevent subsequent stroke appropriate?

In this article, we examine the rationale for current preventive strategies and recommend how to put them into practice.

STROKE SUBTYPE CAN DIRECT TREATMENT

Stroke is a heterogeneous disorder, and one therapy does not fit all strokes. Besides the traditional distinction of ischemic vs hemorrhagic stroke, several subtypes reflect unique pathogenesis or underlying conditions that affect the response to treatment. Strokes have been classified into five subtypes for the purposes of therapeutic trials²:

- Large-artery atherosclerosis: a moderate-to-severe stenosis of a major vessel to the brain associated with the appropriate cortical signs such as aphasia, neglect, or cerebellar signs
- Cardioembolism: directly referable to the heart, eg, due to atrial fibrillation or a mechanical heart valve
- Small-vessel occlusion: usually with no clinical signs of cortical involvement, and usually occurring in patients with diabetes mellitus or hypertension, or both³
- Stroke due to nonatherosclerotic conditions (eg, arterial dissection or hypercoagulable state)

- Stroke with no identifiable cause.

■ MRI AND STROKE PREVENTION

In patients who have had a stroke, magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) can help determine the stroke subtype and the most likely cause of the stroke. MRI has proven much more sensitive and specific than computed tomography in the acute and chronic settings.

Determining the stroke subtype is important, since stroke subtype and cause have the most bearing on the intervention chosen to prevent future strokes in an individual patient. For example, certain patterns of infarction on MRI may aid the clinician in identifying patients with embolic stroke, prompting further investigation of the heart. Patients with strokes involving the cortex, the cortical-subcortical areas, the subcortex (> 15 mm involvement), or both hemispheres have an increased likelihood of an embolic source. Smaller subcortical strokes (< 15 mm) are likely to be due to small-vessel occlusion.⁴ The appearance of multiple infarcts in a linear pattern on diffusion-weighted MRI suggests large-artery thromboembolism (ie, carotid stenosis).⁵

■ GENERAL PRINCIPLES OF PREVENTION

All patients who have had a stroke should receive aspirin therapy and should be carefully monitored. But risk factor reduction goes beyond prescribing aspirin. Prevention of a subsequent stroke requires the identification and aggressive management of any risk factor: eg, hypertension, atherosclerosis, atrial fibrillation, patent foramen ovale, aortic stenosis, and carotid stenosis (**FIGURE 1**). Patients also should be encouraged to participate in exercise programs, alter their diet, and stop smoking.

The choice of antithrombotic agent in addition to aspirin depends largely on the cause of the stroke, risk factors, and on past failures of other drug regimens. As we will discuss later, questions remain about how to make best use of current drugs: eg, whether one agent is more effective than another in preventing subsequent stroke of a specific subtype, or whether certain combinations are better than monotherapy.

Covering all risk factors

Wald and Law⁶ proposed a single pill that would comprise three antihypertensives, aspirin, and a statin, in the hope of reducing the risk of first stroke by 80%. This “polypill” concept is controversial, but it emphasizes that reduction of blood pressure and low-density lipoprotein cholesterol should be part of any plan to reduce the incidence of stroke.

Current prevention strategies are effective when thoroughly applied, but they are often not used as effectively as they could be, as evidenced by a recent audit in the United Kingdom, in which 41% of patients remained hypertensive 6 months after hospitalization for a stroke.⁷

Lowering blood pressure

Numerous studies have shown that controlling hypertension with antihypertensive drugs prevents ischemic stroke. Yet debate persists over which is more important, the class of antihypertensive used or the target blood pressure.⁸


Most of the evidence on antihypertensive therapy and ischemic stroke is from trials of secondary prevention of cardiovascular events; it was found that as a by-product strokes were reduced as well.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)⁹ measured the occurrence of first heart attack in more than 42,000 patients with mild to moderate hypertension who received chlorthalidone, amlodipine, lisinopril, or doxazosin. The investigators found no difference among these drugs in preventing the primary end point of fatal or nonfatal myocardial infarction. Stroke, a secondary end point of the study, occurred more often in the lisinopril group. The authors believed this was because patients receiving chlorthalidone achieved lower systolic blood pressures than those receiving lisinopril.

The Perindopril Protection Against Recurrent Stroke Study (PROGRESS)¹⁰ randomized patients to receive either perindopril or perindopril and indapamide for secondary prevention of stroke. Reducing the blood pressure reduced the risk of subsequent stroke, regardless of stroke subtype.¹⁰ This reiterates the importance of blood pressure reduc-

**Risk factor
reduction goes
beyond
prescribing
aspirin**

■ Sources of risk for ischemic stroke



CCF
©2005

FIGURE 1

tion in stroke prevention.

Is one antihypertensive drug better? At this time, there is no evidence that one antihypertensive drug is superior to another in stroke prevention. The angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) may have intrinsic properties^{11–13} that confer benefits beyond lowering blood pressure, but this hypothesis is still being tested in clinical trials.¹⁴ The advantage of ACE inhibitors and ARBs is largely theoretical at this point.

Statins to lower cholesterol

The ability of statins (HMG-CoA reductase inhibitors) to stabilize atherosclerotic plaque has been studied extensively in cardiology,¹⁵ but evidence has recently surfaced that statins may also provide neuroprotective effects in acute stroke.¹⁶ Still, the evidence linking hypercholesterolemia to stroke has not been convincing.¹⁷

A recent meta-analysis of nearly 80,000 patients with vascular risk factors showed an absolute risk reduction of 0.7% in stroke with statins (21% relative risk reduction).¹⁸

This benefit was confirmed by a recent randomized controlled trial¹⁹ showing an absolute risk reduction of 1.4% and a relative risk reduction of 30% for primary prevention of ischemic stroke favoring simvastatin over placebo. Interestingly, there was no statistical difference in secondary prevention of stroke, but patients with prior strokes did have a lower risk of other major vascular events if they took simvastatin, with a 5.1% absolute risk reduction and 20% relative risk reduction.¹⁹ These results suggest that patients with vascular disease benefit from statins in preventing a first stroke. In addition, patients with a history of stroke may benefit from statins for preventing other vascular events such as myocardial infarction.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial now under way may help answer whether statins are beneficial in secondary prevention of stroke and whether they reduce the severity of the neurologic deficit if a stroke occurs.²⁰ This second question is interesting, since others have observed that patients who have taken statins before a stroke may have shorter hospi-

tal stays²¹ and, possibly, better functional outcomes at longer time intervals.²²

Aspirin

A large meta-analysis showed that aspirin reduces the incidence of stroke, myocardial infarction, or vascular death by 25%.²³

Primary prevention. The Physicians' Health Study reviewed data on primary prevention of stroke in patients taking aspirin²⁴ and found a benefit in prevention of myocardial infarction. However, there was a trend toward an increase in stroke, owing to an increase in hemorrhagic stroke.

In the Women's Health Study, a trial of primary prevention in women, aspirin lowered the risk of stroke without affecting the risk of myocardial infarction or death from cardiovascular causes.²⁵ On the basis of the Women's Health Study, it could be argued that low-dose aspirin to prevent coronary disease in women under age 65 is to be avoided unless the global risk score is very high. But what about the prevention of stroke? We feel that the prescription of aspirin for the primary prevention of stroke and other vascular events should be decided on an individual basis.

Secondary prevention. Numerous clinical trials and meta-analyses have shown that aspirin is efficacious in reducing the risk of a secondary stroke when compared with placebo. Two major trials^{26,27} have shown that giving aspirin within 48 hours of an acute stroke has a small but statistically significant benefit in reducing the occurrence of a second ischemic stroke. In the International Stroke Trial (IST), patients who received aspirin were less likely to have another stroke within 14 days of the first stroke (absolute risk reduction 0.9%, relative risk reduction 23%).²⁶ In the Chinese Acute Stroke Trial (CAST), patients receiving aspirin were less likely to have a recurrent stroke at 30-day follow-up (absolute risk reduction 0.5%, relative risk reduction 23%).²⁷

The debate has been over the optimal dosing of aspirin. The Dutch Transient Ischemic Attack Trial compared 30 mg of aspirin with 283 mg of aspirin and showed no difference in stroke reduction rates.²⁸ A more recent trial compared low-dose aspirin (81 mg

We have no proof yet that one antihypertensive drug is best in preventing stroke

or 325 mg) vs high-dose aspirin (650 mg or 1,300 mg) in patients undergoing carotid endarterectomy. No difference was found for stroke, myocardial infarction, or death at 30 days.²⁹ A meta-analysis of these trials showed no difference in stroke reduction rates on the basis of aspirin dosage, with doses ranging from 30 to 1,300 mg daily.³⁰

The US Food and Drug Administration (FDA) has since recommended that a daily dose between 50 and 325 mg is acceptable in the secondary prevention of stroke.³¹ We recommend 81 mg and consideration of platelet aggregation studies if there is any doubt about efficacy, eg, due to noncompliance or recurrent clinical events.

Despite these results, aspirin is still underprescribed for patients being discharged from the hospital after stroke.

Aspirin resistance

Some patients still have a vascular event even if they are taking aspirin. Researchers have found that some patients are predisposed to biochemical aspirin resistance, as measured by platelet aggregation studies. A study of 326 patients with stable coronary artery disease found that 5.2% had resistance to aspirin at a dose of 325 mg, and that this resistance increased the risk of a vascular event fourfold in a multivariate model.³² Another group considered stroke patients only and found that 37% of 129 patients had normal platelet function despite taking aspirin in doses ranging from 81 to 325 mg daily. Interestingly, they found a twofold increase in resistance in patients taking a lower dose of aspirin.³³

These findings have prompted consideration of other antiplatelet drugs for stroke prevention, in addition to checking for platelet aggregation in patients in whom aspirin therapy fails.

Clopidogrel

Clopidogrel is an irreversible inhibitor of platelet function that blocks the adenosine diphosphate receptor, thereby preventing the aggregation of platelets. There are no published trials of clopidogrel in the primary prevention of stroke, but there are two major trials of clopidogrel in secondary prevention.

The Clopidogrel vs Aspirin in Patients at

Risk of Ischaemic Events (CAPRIE) study³⁴ was a controlled trial of about 20,000 patients, randomized to take aspirin 325 mg or clopidogrel 75 mg daily. This study showed a 0.5% absolute risk reduction and an 8.7% relative risk reduction favoring the clopidogrel group for the combined primary end point (myocardial infarction, stroke, or vascular death). In the subgroup with previous stroke, there was a 7.3% relative risk reduction favoring clopidogrel, but the difference was not statistically significant.

The results of CAPRIE have prompted numerous studies to determine if clopidogrel is superior to aspirin in vascular disease. The recently completed Management of Atherothrombosis with Clopidogrel in High-risk Patients with Recent TIA or Ischemic Stroke (MATCH) trial³⁵ compared clopidogrel 75 mg plus low-dose aspirin against aspirin alone for the prevention of the primary end point of vascular death, myocardial infarction, or stroke. The results revealed an absolute risk reduction of 1% and a relative risk reduction of 6.4% for the primary end point with combination therapy, but these findings were not statistically significant. The incidence of major bleeding events was also higher with combination therapy (1.94% vs 0.58%, $P < .001$).

More data are needed to determine if clopidogrel is superior to aspirin in preventing ischemic stroke in high-risk patients, but it appears to be beneficial with regard to secondary prevention of vascular events.

Limitations of clopidogrel

Limitations of clopidogrel include a delay in onset of action of several hours, irreversibility of action, and possible resistance. Third-generation thienopyridines are under evaluation in clinical studies, and preliminary data suggest that prasugrel may address some of these shortcomings.

Clopidogrel resistance. Although less well known than aspirin resistance, resistance to clopidogrel is probably caused mostly by inefficient metabolism of the prodrug clopidogrel to its active metabolite. In a recent study by Alberts et al,³⁶ clopidogrel resistance was shown in more than 30% of patients taking one or two antiplatelet therapies.

We recommend aspirin 81 mg for secondary prevention of stroke

Dipyridamole

Dipyridamole is a platelet phosphodiesterase inhibitor that allows cyclic adenosine monophosphate to remain elevated, thereby preventing platelet aggregation. It also acts as a vasodilator and prevents platelet adhesion to the vessel wall.³⁷ Of note, the gene encoding phosphodiesterase-4D has recently been shown to confer a risk of ischemic stroke: in particular, large-artery atherosclerosis and cardiogenic subtypes.³⁸

So far, dipyridamole has only been studied in the secondary prevention of stroke.

One controlled study in 1983 failed to show any effectiveness of dipyridamole in combination with aspirin in reducing the risk of stroke when compared with aspirin alone.³⁹ The first European Stroke Prevention Study⁴⁰ compared dipyridamole plus aspirin against placebo and found a 38% relative risk reduction in stroke with combination therapy. This was felt to be an additive effect of dipyridamole and prompted the second European Stroke Prevention Study.⁴¹ This was a factorial study with one arm comparing extended-release dipyridamole and aspirin vs aspirin alone in 6,600 patients. This study found that extended-release dipyridamole 200 mg twice a day along with aspirin 50 mg a day was superior to aspirin monotherapy (50 mg), with an absolute risk reduction of 2.9% and a relative risk reduction of 23%. It was also more effective than placebo, with an absolute risk reduction of 5.6% and a relative risk reduction of 37%. Headaches were commonly noted by patients who discontinued the medications, and bleeding rates were not significantly higher than with aspirin monotherapy.

Another ongoing clinical trial⁴² has been enrolling patients in Europe and Australia to determine if the combination of aspirin and dipyridamole is superior to aspirin alone or anticoagulants in preventing secondary strokes and other vascular events, including myocardial infarction and death.

Warfarin for secondary prevention: Indications narrowing

The indications for warfarin in the secondary prevention of stroke have been gradually narrowing.^{43,44} The Warfarin-Aspirin Symptomatic Intracranial Disease study⁴³ compared high-dose

aspirin (1,300 mg/day) with warfarin in patients with intracranial atherosclerosis. The study was stopped prematurely because patients in the warfarin group had a higher rate of hemorrhage, and because no difference was noted in the two groups with regards to stroke prevention.

The Warfarin-Aspirin Recurrent Stroke Study⁴⁴ compared aspirin 325 mg daily vs warfarin and excluded patients with symptomatic carotid stenosis and atrial fibrillation. No difference in rates of stroke recurrence, hemorrhage, or death was noted between the two groups.

Warfarin, heart failure, and stroke. No randomized controlled trial has yet been published that tested warfarin in the primary or secondary prevention of stroke in patients with heart failure or reduced ejection fraction. However, two trials are under way to test warfarin and antiplatelet agents in patients with low ejection fraction.⁴⁵

■ ATRIAL FIBRILLATION

Atrial fibrillation accounts for nearly 50% of cardioembolic strokes and confers a risk of recurrent stroke of roughly 5% a year,⁴⁶ increasing with age.⁴⁷

Warfarin is beneficial

The relative risk reduction in prevention of stroke ranges from 27% to 48% with warfarin vs aspirin,^{48–50} and 47% to 86% with warfarin vs placebo.^{48,51} A meta-analysis of the five major trials showed that warfarin was superior to placebo, conferring an absolute risk reduction of 3.1% and a relative risk reduction of 68% in the primary prevention of stroke.⁴⁶ There is an increased risk of major bleeding with warfarin, but the number of strokes prevented (23 per 100 patient-years) is greater than the number of bleeding complications (9 per 100 patient-years).⁵² In addition, warfarin has been found to be effective in the secondary prevention of stroke when compared with aspirin or placebo.⁴⁸

Holter monitoring aids detection

Unfortunately, atrial fibrillation may be missed because it can be episodic in up to 30% of patients.⁵³ This often poses a problem for the clinician who suspects a cardioembolic

Atrial fibrillation accounts for nearly 50% of cardioembolic strokes

source of the stroke. The diagnosis is often missed because the length of the recording of a patient's rhythm is inadequate.

Holter monitoring may increase detection in an additional 6.1% of patients with paroxysmal atrial fibrillation.^{54,55} A recent report studied 149 consecutive patients admitted for acute stroke and found that a routine electrocardiogram (ECG) showed atrial fibrillation in 2.7% of patients. When a 24-hour Holter monitor was placed on patients with a normal ECG, an additional 5% of patients were found to have atrial fibrillation. The most interesting part of this study was that a 7-day event-loop recorder documented this rhythm disturbance in 5.7% of patients with a negative ECG and negative 24-hour Holter monitoring.⁵⁶

Alternatives to warfarin

An exciting new alternative to warfarin that showed promise in patients with atrial fibrillation was Ximelagatran, an oral anticoagulant and a direct thrombin inhibitor that does not require coagulation monitoring and has no interactions with food or other medications.⁵⁸ It was compared with warfarin in a multicenter trial, which found no statistical difference in safety or efficacy between the two groups. However, Ximelagatran was found to be toxic to the liver, with a fatality rate in the order of 1 per 5,000 patients. In September 2004, an FDA panel turned down approval of the drug due to these concerns, so its future availability in the United States is in doubt.

Another intriguing development is an experimental device implanted via catheterization to occlude the percutaneous left atrial appendage.⁵⁸ This could be an option for patients with contraindications to warfarin. In this procedure, a self-expanding cage covered with a polymeric membrane could be implanted to occlude the left atrial appendage, the location of thrombus in patients with atrial fibrillation nearly 90% of the time.⁵⁹ Early experience has shown that this procedure is technically feasible,⁶⁰ but it is unclear if these devices reduce the risk of stroke.

■ PATENT FORAMEN OVALE

Although patent foramen ovale has long been recognized as a cause of paradoxical embolism

and stroke, the elusive nature of the clot makes this a challenging diagnosis. An exception is if a young patient who is known to have a venous clot has an embolic stroke after performing a Valsalva maneuver.

Three major questions remain:

- Does patent foramen ovale confer an increased risk of subsequent stroke?
- Does an atrial septal aneurysm increase this risk?
- What is the optimal therapy?

Two prospective randomized control studies help answer the first question and give insights into the other two questions.

Patent foramen ovale and stroke risk

Mas et al⁶¹ reported 581 patients under age 55 with cryptogenic stroke, who were followed for 4 years. In those receiving aspirin, they found no difference in stroke recurrence rates in patients without an atrial defect compared with those with a patent foramen ovale or atrial septal aneurysm. They did note an increase in the yearly rate of recurrent stroke or transient ischemic attack in patients with both patent foramen ovale and atrial septal aneurysm compared with patients without an atrial septal defect (4.8% vs 1.6%, hazard ratio 3.91, 95% confidence interval 1.59–9.59).

The Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS)⁶² is particularly valuable because of its large cohort and prospective design. Patients with a recent ischemic stroke enrolled in the Warfarin-Aspirin Recurrent Stroke study were randomized to treatment with warfarin or aspirin. A subgroup of these patients underwent transesophageal echocardiography after exclusion of an alternative cardiogenic source and severe carotid stenosis. The prevalence of patent foramen ovale was greater among those with stroke of unknown cause (39.2%) than among those in whom a potential cause of stroke could be identified (29.9%; $P < .02$); this was particularly true with respect to patients with a large patent foramen ovale (20.0% vs 9.7%, $P < .001$). However, no significant difference was found in the rate of recurrent stroke or death over 2 years between those with a patent foramen ovale of any size and those without a patent foramen ovale. Furthermore, there were no significant differences in primary event

Holter monitoring may help detect atrial fibrillation in patients with acute stroke

rates between patients randomized to warfarin or aspirin (325 mg/day), regardless of whether the cause of the index stroke was identifiable or unidentifiable.

Drug vs surgical therapy

Endovascular closure to treat patent foramen ovale is becoming an increasingly used option.⁶³ The FDA has published guidelines regarding which patients may qualify for percutaneous closure via the humanitarian device exemption.⁶⁴ Patients can meet the exemption criteria if they have a recurrent cryptogenic stroke despite being on therapeutic doses of warfarin. This is confusing, since we still do not have enough evidence that warfarin is superior to aspirin in this patient population. A recently initiated trial will compare medical therapy (any antithrombotic) with endovascular closure of patent foramen ovale in preventing recurrent stroke.⁶⁵

American Academy of Neurology guidelines

Based on the above findings, the American Academy of Neurology stated that patients with a patent foramen ovale and stroke of unidentifiable cause are not at higher risk of a subsequent stroke when compared with patients without patent foramen ovale and with stroke of unidentifiable cause.⁶⁶ The presence of an atrial septal aneurysm along with a patent foramen ovale may pose a higher risk in younger patients.

The Academy also felt there was insufficient evidence to determine optimal therapy in comparing aspirin vs warfarin for this group of patients, and even less evidence with regard to the effectiveness of percutaneous closure.⁶⁶

AORTIC ARCH ATHEROMA

Patients who are older and have hypertension are at increased risk of developing atherosclerotic disease of the aortic arch.⁶⁷ These atheromas may be responsible for cerebral emboli in patients with stroke of unidentifiable cause. Patients with an atheroma larger than 4 mm, ulcerated plaque, mobile atheroma, or extension of atheroma into the origin of the carotid or vertebral arteries are at increased risk of future stroke.^{68–70}

At this time it is unclear which antithrombotic agents should be used to prevent stroke in these patients. A trial now under way is comparing clopidogrel and aspirin vs aspirin monotherapy to determine if intensified antiplatelet therapy can reduce stroke risk.⁷¹

Surgery. The role of surgical intervention such as aortic arch replacement is unknown. However, the presence of clot or atheroma in the aortic arch increases the chance of perioperative stroke at least four-fold.⁷² Surgical procedures to address this risk have been devised^{73,74} and may one day become acceptable options for secondary stroke prevention in patients with aortic arch atherosclerosis.

CAROTID STENOSIS

Patients with symptoms of stroke or transient ischemic attack should undergo ultrasonography of the carotid artery as part of the etiologic workup. A carotid lesion is considered symptomatic if the patient has a stroke or transient ischemic attack with symptoms that could be due to ischemia in the part of the brain supplied by the blocked artery. Stroke associated with carotid stenosis can be due to a large arterial embolus or, less frequently, to exhausted cerebrovascular reserve in the ipsilateral carotid territory.

Key management issues

Two issues need consideration when managing patients with carotid stenosis. First, mild stenosis (< 50%) or moderate stenosis (51%–69%) often progresses, and the further narrowing increases the risk of stroke or transient ischemic attack.⁷⁵ Second, in patients with carotid stenosis of 60% to 69%, stroke is more likely to have been due to cardioembolism than it is in patients with a higher degree of stenosis.⁷⁶ It is imperative to understand the cause of the stroke before assigning a patient to surgery for a symptomatic lesion.

Preventing a first stroke in carotid artery stenosis

Two studies examined the primary prevention of ischemic stroke in patients with carotid artery stenosis.^{77,78}

Several antiplatelet drug options are available in aortic arch atheroma



Endarterectomy vs medical therapy. The Asymptomatic Carotid Atherosclerosis study⁷⁷ included only patients with asymptomatic carotid stenosis of 60% to 99%. These patients were randomized to endarterectomy or medical therapy. The rate of stroke or death at 5-year follow-up favored surgery (5.1% vs 11%, $P < .004$).⁷⁷ However, the results may not be generalizable to the community at large because the surgeons in this study had lower complication rates than those in other trials.

The Asymptomatic Carotid Surgery trial⁷⁸ also found that endarterectomy reduced the risk of ipsilateral stroke, and the results are consistent with the 5-year results of the Asymptomatic Carotid Atherosclerosis study.

The North American Symptomatic Carotid Endarterectomy trial, a secondary stroke prevention trial, showed that patients with a symptomatic stenosis of greater than 70% had a nearly threefold decrease (9% vs 26%, $P < .001$) in ipsilateral stroke with surgery vs drug therapy at 2-year follow-up.⁷⁹

Stenting. Recently, the advent of carotid stenting has increased treatment options for patients with carotid artery stenosis. But it is not yet known which patients who have had no previous stroke will benefit the most, because most data on stenting are for secondary prevention, although some trials have included asymptomatic carotid stenosis.

The Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial⁸⁰ compared stenting with endarterectomy in high-risk surgical patients. All patients in this study had carotid disease; some were asymptomatic, and others had already had a transient ischemic attack or stroke. Patients who underwent stenting had a significantly lower rate of myocardial infarction, stroke, or death at 30-day follow-up (5.8% vs 12.6%, $P < .047$). At 1 year, the rate of ipsilateral stroke was 3.8% in the stent group vs 5.3% in the endarterectomy group.

In contrast, an earlier, methodologically less stringent study comparing carotid endarterectomy and carotid artery stenting with a self-expanding endoprosthesis⁸¹ was stopped early because patients undergoing stenting had a stroke rate of 12.1% at 30 days, compared with 4.5% in the endarterectomy

group. It is now felt that these results were related to operator inexperience rather than to the angioplasty and stenting procedure.

The Carotid Revascularization Endarterectomy vs Stenting Trial (CREST)⁸² is randomizing patients to endarterectomy or stenting and, we hope, will determine which procedure is superior in a more generalizable group of patients.

At our institution, if a patient has a symptomatic carotid stenosis greater than 70%, we offer carotid endarterectomy or randomization into one of our carotid stenting trials. Patients with severe asymptomatic carotid stenosis are offered revascularization on a case-by-case basis. At this time, patients should be offered carotid stenting as an option only as part of a clinical trial.

■ SERUM MARKERS

Recently, there has been interest in serum markers such as homocysteine and C-reactive protein to identify patients who might benefit from treatment to prevent ischemic stroke.

Homocysteine

Reduction of homocysteine levels with pyridoxine, vitamin B₁₂, and folic acid was found to reduce the risk of coronary restenosis after revascularization procedures.⁸³ Furthermore, homocysteine levels greater than 15 $\mu\text{mol/L}$ (normal 5–15) have been shown to be an independent risk factor for recurrent stroke in multivariate regression models.⁸⁴ However, the only randomized controlled study to date did not show a reduction in recurrent stroke after initiation of vitamin therapy to reduce moderately elevated levels of serum homocysteine.⁸⁵ The major criticism of this study was that the mean levels of homocysteine for the cohort were lower than levels reported elsewhere as putting patients at a higher risk of stroke. Another concern was that the follow-up period was too short, and possible benefits could have been missed.

For now, routine measurement of homocysteine levels has no role in stroke prevention.

C-reactive protein

C-reactive protein is a marker of inflammation. It is associated with atherosclerosis and is a pre-

In mild or moderate carotid stenosis, narrowing can progress, raising stroke risk

dictor of acute coronary events.⁸⁶ Elevations have also been associated with an increased risk of recurrent ischemic stroke in patients with large-artery atherosclerosis.⁸⁷ Angiotensin-converting enzyme inhibitors and statins reduce levels of C-reactive protein.^{88,89}

Further research is needed to define the role of C-reactive protein elevations in stroke patients. Until we know more, routine screening for this marker is not indicated.

Lipoprotein-associated phospholipase A₂

Given the prominent role of inflammation in coronary artery disease, there is growing evidence to suggest that many strokes manifest from the same process. Lipoprotein-associated

phospholipase A₂ is a novel inflammatory marker which has been shown to be associated with inflammation and which may actively promote inflammation.^{90,91}

■ LIFESTYLE MODIFICATIONS

Each patient should be counseled on lifestyle modifications. These should include smoking cessation, 30 minutes of exercise on most days of the week, a balanced diet, and avoidance of large quantities of alcohol. All of these modifications have been recommended by the American Heart Association's Scientific Committee for primary and secondary stroke prevention.⁹²

■ REFERENCES

- Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet* 2003; 361:717-725.
- Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993; 24:35-41.
- Fisher CM. Lacunar stroke and infarcts: a review. *Neurology* 1982; 32:871-876.
- Kang DW, Chalela JA, Ezzeddine MA, et al. Association of ischemic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. *Arch Neurol* 2003; 60:1730-1734.
- Kastrup A, Schulz JB, Mader I, et al. Diffusion-weighted MRI in patients with symptomatic internal carotid artery disease. *J Neurol* 2002; 249:1168-1174.
- Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. *BMJ* 2003; 326:1419.
- Rudd AG, Lowe D, Hoffman A, et al. Secondary prevention for stroke in the United Kingdom: results from the National Sentinel Audit for stroke. *Age Aging* 2004; 33:280-286.
- Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 2003; 362:1527-1535.
- Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; 360:1903-1913.
- Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. *Stroke* 2004; 35:116-121.
- Okamoto K, Takai S, Sasaki S, et al. Trandolapril reduces infarction area after middle cerebral artery occlusion in rats. *Hypertens Res* 2002; 25:583-588.
- Engelhorn T, Goerike S, Doerfler A, et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. *J Cereb Blood Flow Metab* 2004; 24:467-474.
- Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359:995-1003.
- Sacco RL, for the PROFESS Steering Committee and Study Group. Prevention regimen for effectively avoiding second strokes (PROFESS). Presented at the International Stroke Conference; February 5-7, 2004; San Diego, CA.
- Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. *JAMA* 1998; 279:1643-1650.
- Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. *Stroke* 1999; 30:1969-1973.
- Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. *Lancet* 1995; 346:1647-1653.
- Cheung BMY, Lauder IJ, Lau CP, et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol* 2004; 57:640-651.
- Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004; 363:757-767.
- The SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. *Cerebrovasc Dis* 2003; 16:389-395.
- Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. *Stroke* 2001; 32:1112-1115.
- Marti-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. *Stroke* 2004; 35:1117-1123.
- Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists Collaboration. *BMJ* 1994; 308:81-106.
- Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1989; 321:129-135.
- Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005; 352:1293-1304.
- International Stroke Trial Collaborative Group. International stroke trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. *Lancet* 1997; 349:1569-1581.
- CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute stroke trial) Collaborative Group. *Lancet* 1997; 349:1641-1649.
- The Dutch TIA Trial Study Group. A comparison of two doses of



- aspirin (30 mg vs. 283 mg a day) in patients after transient ischemic attack or minor ischemic stroke. *N Engl J Med* 1991; 325:1261–1266.
29. **Taylor DW, Barnett HJ, Haynes RB, et al.** Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial: ASA and Carotid Endarterectomy (ACE) Trial Collaborators. *Lancet* 1999; 353:2179–2184.
 30. **Algra A, van Gijn J.** Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. *J Neurol Neurosurg Psychiatry* 1996; 60:197–199.
 31. **Food and Drug Administration.** Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. *Fed Regist* 1998; 63:56802–56819.
 32. **Gum PA, Marchant KK, Welsh PA, et al.** A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003; 41:961–965.
 33. **Alberts MJ, Bergman DL, Molner E, et al.** Antiplatelet effect of aspirin in patients with cerebrovascular disease. *Stroke* 2004; 35:175–178.
 34. **CAPRIE Steering Committee.** A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996; 348:1329–1339.
 35. **Diener HC, Bogousslavsky J, Brass LM, et al.** Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; 364:331–337.
 36. **Alberts MJ, Bergman D, Brooks K, Bernstein R, Ramsey G, Lindholm P.** Clopidogrel resistance in patients with cerebrovascular disease [abstract]. *Stroke* 2005; 36:517–518.
 37. **FitzGerald GA.** Dipyridamole. *N Engl J Med* 1987; 316:1247–1257.
 38. **Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al.** The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. *Nat Genet* 2003; 35:131–138.
 39. **Bousser MG, Eschwege E, Haguenu M, et al.** AICLA: controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. *Stroke* 1983; 14:5–14.
 40. **European Stroke Prevention Study Group.** The European Stroke Prevention study. *Stroke* 1990; 21:1122–1130.
 41. **Diener HC, Cunha L, Forbes C, et al.** European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996; 143:1–13.
 42. **De Schryver EL.** The European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. *Cerebrovasc Dis* 2000; 10:147–150.
 43. **Mohr JP, Thompson JL, Lazar RM, et al, for the Warfarin-Aspirin Recurrent Stroke Study Group.** A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 2001; 345:1444–1451.
 44. **Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators.** Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. *Neuroepidemiology* 2003; 22:106–117.
 45. **Pullicino RM, Halperin JL, Thompson JL.** Stroke in patients with heart failure and reduced left ventricular ejection fraction. *Neurology* 2000; 54:288–294.
 46. **Atrial Fibrillation Investigators.** Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994; 154:1449–1457.
 47. **Wolf PA, Abbott RD, Kannel WB.** Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991; 22:983–988.
 48. **EAFT (European Atrial Fibrillation Trial) Study Group.** Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. *Lancet* 1993; 342:1255–1266.
 49. **Petersen P, Boysen G, Godtfredsen J, et al.** Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. *Lancet* 1989; 1:175–178.
 50. **Stroke Prevention in Atrial Fibrillation Investigators.** Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *Lancet* 1994; 343:687–691.
 51. **Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.** The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990; 323:1505–1511.
 52. **Van Walraven C, Hart RG, Singer DE, et al.** Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. *JAMA* 2002; 288:2441–2448.
 53. **Lin HJ, Wolf PA, Benjamin EJ, et al.** Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. *Stroke* 1995; 26:1527–1530.
 54. **Schuchert A, Behrens G, Meinertz T.** Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke. *Pacing Clin Electrophysiol* 1999; 22:1082–1084.
 55. **Roche F, Gaspoz JM, Da Costa A, et al.** Frequent and prolonged asymptomatic episodes of paroxysmal atrial fibrillation revealed by automatic long-term event recorders in patients with a negative 24-hour Holter. *Pacing Clin Electrophysiol* 2002; 25:1587–1593.
 56. **Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R.** Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. *Stroke* 2004; 35:1647–1651.
 57. **Halperin JL, for the SPORTIF Investigators.** Presented at: American Heart Association Scientific Sessions; November 9–12, 2003; Orlando, FL.
 58. **Nakai T, Lesh MD, Gerstenfeld EP, et al.** Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism. *Circulation* 2002; 105:2217–2222.
 59. **Blackshear JL, Odell JA.** Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. *Ann Thorac Surg* 1996; 61:755–759.
 60. **Sievert H, Lesh MD, Trepels T, et al.** Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation. *Circulation* 2002; 105:1887–1889.
 61. **Mas JL, Arquiza C, Lamy C, et al.** Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. *N Engl J Med* 2001; 345:1740–1746.
 62. **Homma S, Sacco RL, Di Tullio MR, et al.** Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. *Circulation* 2002; 105:2625–2631.
 63. **Windecker S, Wahl A, Chatterjee T, et al.** Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. *Circulation* 2000; 101:893–898.
 64. **US Food and Drug Administration.** Humanitarian Device Exemption. HDE #H990011 February 2000.
 65. **NMT Medical Website for CLOSURE I Trial:** www.nmtmedical.com/closure1/. Accessed March 31, 2005.
 66. **Messé SR, Silverman IE, Kizer JR, et al.** Practice parameter: Recurrent stroke with patent foramen ovale and atrial septal aneurysm. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2004; 62:1042–1050.
 67. **Davila-Roman VG, Barzilai B, Wareing TH, et al.** Atherosclerosis of the ascending aorta: prevalence and role as an independent predictor of cerebrovascular events in cardiac patients. *Stroke* 1994; 25:2010–2016.
 68. **Amarenco P, Duyckaerts C, Tzourio C, et al.** The prevalence of ulcerated plaques in the aortic arch in patients with stroke. *N Engl J Med* 1992; 326:221–225.
 69. **The French Study of Aortic Plaques in Stroke Group.** Atherosclerotic



- disease of the aortic arch as a risk factor for recurrent ischemic stroke. *N Engl J Med* 1996; 334:1216–1221.
70. Fujimoto S, Yasaka M, Otsubo R, et al. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. *Stroke* 2004; 35:1426–1429.
 71. Aortic Arch Related Cerebral Hazard Trial Web Site, www.strokeconference.org/sc_includes/pdfs/CTP2.pdf. Accessed March 31, 2005.
 72. Hagl C, Ergin MA, Galla JD, et al. Neurologic outcome after ascending aorta-aortic arch operations: effect of brain protection technique in high-risk patients. *J Thorac Cardiovasc Surg* 2001; 121:1107–1121.
 73. Gillinov AM, Lytle BW, Hoang V, et al. The atherosclerotic aorta at aortic valve replacement: surgical strategies and results. *J Thorac Cardiovasc Surg* 2000; 120:957–963.
 74. Svensson LG, Crawford ES. *Cardiovascular and Vascular Disease of the Aorta*. Philadelphia: WB Saunders, 1997.
 75. Bertges DJ, Muluk V, Whittle J, et al. Relevance of carotid stenosis progression as a predictor of ischemic neurological outcomes. *Arch Intern Med* 2003; 163:2285–2289.
 76. Barnett HJM, Gunton RW, Eliasziw M, et al. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. *JAMA* 2000; 283:1429–1436.
 77. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA* 1995; 273:1421–1428.
 78. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet* 2004; 363:1491–1502.
 79. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med* 1991; 325:445–453.
 80. Yadav JS. Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE). Presented at the American Heart Association Scientific Meeting; November 17–20, 2002; Chicago, IL.
 81. Alberts MJ. Results of a multicenter prospective randomized control trial of carotid stenting vs. carotid endarterectomy [abstract]. *Stroke* 2001; 32:325.
 82. Hobson II RW, Howard VJ, Brott TG, et al. Organizing the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): National Institutes of Health, Health Care Financing Administration, and industry funding. *Curr Control Trials Cardiovasc Med* 2001; 2:160–164.
 83. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001; 345:1593–1600.
 84. Sacco RL, Anand K, Lee HS, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort. The Northern Manhattan Study. *Stroke* 2004; 35:2263–2269.
 85. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004; 291:565–575.
 86. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. *Circulation* 1998; 97:2007–2011.
 87. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. *Stroke* 2003; 34:2463–2468.
 88. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. *Stroke* 2003; 34:2922–2929.
 89. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med* 2001; 344:1959–1965.
 90. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. *J Infect Dis* 2000; 181(suppl 3):S462–S472.
 91. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2004; 109:837–842.
 92. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke* 2001; 32:280–299.

ADDRESS: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org.